SCHEMBL16644514

SCHEMBL16644514

Cc1ccc(F)c(NC(=O)c2ccc(C)c(C#Cc3cnc4cccnn34)c2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.66
ABL1 P00519 13/20 0.66
ROR1 Q01973 6/20 0.64
GAK O14976 1/20 0.55
MLNR O43193 1/20 0.55
RIPK2 O43353 1/20 0.55
JAK2 O60674 1/20 0.55
NR1I2 O75469 1/20 0.55
ABCB11 O95342 1/20 0.55
MAP4K4 O95819 1/20 0.55
EGFR P00533 1/20 0.55
NR3C1 P04150 1/20 0.55
ERBB2 P04626 1/20 0.55
NTRK1 P04629 1/20 0.55
LCK P06239 1/20 0.55
FYN P06241 1/20 0.55
PGR P06401 1/20 0.55
YES1 P07947 1/20 0.55
LYN P07948 1/20 0.55
RET P07949 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19317721 0.83 ROR1 (0.79) CSF1RABL1ROR1CYP3A4KIT
SCHEMBL16644466 0.83 CSF1R (0.75) CSF1RABL1ROR1LCKCYP3A4
SCHEMBL16644461 0.81 ABL1 (0.84) CSF1RABL1ROR1GAKMLNR
SCHEMBL16085011 0.80 CSF1R (0.65) CSF1RABL1ROR1GAKMLNR
SCHEMBL16250614 0.80 ABL1 (0.80) CSF1RABL1ROR1GAKMLNR
SCHEMBL29506341 0.80 CSF1R (0.67) CSF1RABL1ROR1CYP3A4KCNH2
SCHEMBL589881 0.80 CSF1R (0.67) CSF1RABL1ROR1CYP3A4KCNH2
SCHEMBL15096062 0.80 ROR1 (0.67) CSF1RABL1ROR1GAKMLNR
SCHEMBL16644465 0.79 ABL1 (1.00) CSF1RABL1ROR1GAKMLNR
SCHEMBL16644588 0.79 ABL1 (0.76) CSF1RABL1ROR1GAKMLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150105377-A1 Methods and Compositions for RAF Kinase Mediated Diseases ARIAD PHARMACEUTICALS, INC. 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105377-A1 Methods and Compositions for RAF Kinase Mediated Diseases BRAF, RAF1, NRAS CSF1R 2599/4885ABL1 75/4885ROR1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.